Prognostic significance of dysregulation of shelterin complex and its correlation with telomere length and cytogenetics in multiple myeloma
Tóm tắt
MM (multiple myeloma) is a bone marrow disease with the accumulation of malignant plasma cells characterized by the neoplastic transformation of differentiated B cells. The onset and progression of cancer are greatly influenced by telomere dysfunction. We aimed to study the biomarker potential and prognostic significance of shelterin complex and hTERT. Telomere length and gene expression were measured using real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR), and these results were further correlated with clinical parameters. Our study showed increased expression of all genes in complex, hTERT, and TL in MM (n = 72) in comparison with controls (n = 31). TRF2 (P = 0.025) and hTERT (P = 0.0002) displayed significant association among cytogenetic analysis. The receiver operative curve showed POT1 and RAP1 with a greater area under the curve (AUC). RAP1 (P = 0.020) and hTERT (P = 0.037) displayed to be independent prognostic markers for overall survival. Clinical parameters and genes were observed to be significantly correlated. Our study findings showed variation in telomere-associated genes and suggest the participation of these genes as prognostic markers in MM. These results all together highlight the evaluation and role of genes involved in telomeric alteration and TL, providing the opportunity to study new therapeutic approaches in patients with MM.
Tài liệu tham khảo
Xu D, Zheng C, Bergenbrant S, Holm G, Björkholm M, Yi Q, Gruber A (2001) Telomerase activity in plasma cell dyscrasias. Br J Cancer 84(5):621–625
Li S, Jiang Y, Li A, Liu X, Xing X, Guo Y, Xu Y, Hao Y, Zheng C (2017) Telomere length is positively associated with the expression of IL-6 and MIP-1α in bone marrow mesenchymal stem cells of multiple myeloma. Mol Med Rep 16(3):2497–2504
Kumar R, Khan R, Gupta N, Seth T, Sharma A, Kalaivani M, Sharma A (2018) Identifying the biomarker potential of telomerase activity and shelterin complex molecule, telomeric repeat binding factor 2 (TERF2), in multiple myeloma. Leuk Lymphoma 59(7):1677–1689
Panero J, Arbelbide J, Fantl DB, Rivello HG, Kohan D, Slavutsky I (2010) Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma. Mol Med 16(11):471–478
De Lange T (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19(18):2100–2110
Lin X, Gu J, Lu C, Spitz MR, Wu X (2006) Expression of telomere-associated genes as prognostic markers for overall survival in patients with non–small cell lung cancer. Clin Cancer Res 12(19):5720–5725
MWer S, Dykes D, Polesky H, (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 25(4):402–408
Moazzam M, Yim T, Kumaresan V, Henderson DC, Farrer LA, Zhang H (2021) Analysis of telomere length variation and Shelterin complex subunit gene expression changes in ethanol-exposed human embryonic stem cells. J Psychiatric Res 143:543–549
Kumar R, Gupta N, Sharma A (2018) Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules. Mol Biol Rep 45(6):2429–2439
Matsutani N, Yokozaki H, Tahara E, Tahara H, Kuniyasu H, Haruma K, Chayama K, Yasui W, Tahara E (2001) Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol 19(3):507–512
Oh BK, Kim YJ, Park C, Park YN (2005) Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol 166(1):73–80
Bellon M, Datta A, Brown M, Pouliquen JF, Couppie P, Kazanji M, Nicot C (2006) Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia. Int J Cancer 119(9):2090–2097
Smogorzewska A, van Steensel B, Bianchi A, Oelmann S, Schaefer MR, Schnapp G, de Lange T (2000) Control of human telomere length by TRF1 and TRF2. Mol Cell Biol 20(5):1659–1668
Van Steensel B, De Lange T (1997) Control of telomere length by the human telomeric protein TRF1. Nature 385(6618):740–743
Yamada M, Tsuji N, Nakamura M, Moriai R, Kobayashi D, Yagihashi A, Watanabe N (2002) Down-regulation of TRF1, TRF2 and TIN2 genes is important to maintain telomeric DNA for gastric cancers. Anticancer Res 22(6A):3303–3307
Yamada K, Yajima T, Yagihashi A, Kobayashi D, Koyanagi Y, Asanuma K, Yamada M, Moriai R, Kameshima H, Watanabe N (2000) Role of human telomerase reverse transcriptase and telomeric-repeat binding factor proteins 1 and 2 in human hematopoietic cells. Jpn J Cancer Res 91(12):1278–1284
La Torre D, de Divitiis O, Conti A, Angileri FF, Cardali S, Aguennouz MH, Aragona M, Panetta S, d’Avella D, Vita G, La Torre F (2005) Expression of telomeric repeat binding factor-1 in astroglial brain tumors. Neurosurg 56(4):802–810
Klapper W, Krams M, Qian W, Janssen D, Parwaresch R (2003) Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Bri J Cancer 89(4):713–719
Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E, Koering CE, Gilson E (2003) Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res 9(3):1105–1111
Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H, Yasui W (2004) Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 64(2):523–529
Karlseder J, Smogorzewska A, de Lange T (2002) Senescence induced by altered telomere state, not telomere loss. Science 295(5564):2446–2449
Panero J, Stanganelli C, Arbelbide J, Fantl DB, Kohan D, Rivello HG, Rabinovich GA, Slavutsky I (2014) Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression. Blood Cells Mol Dis 52(2–3):134–139
Li B, Oestreich S, De Lange T (2000) Identification of human Rap1: implications for telomere evolution. Cell 101(5):471–483
Yasui W, Tahara E, Tahara H, Fujimoto J, Naka K, Nakayama J, Ishikawa F, Ide T, Tahara E (1999) Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach. Jpn J Cancer Res 90:589–595
Pardo B, Marcand S (2005) Rap1 prevents telomere fusions by nonhomologous end joining. EMBO J 24(17):3117–3127
Hyatt S, Jones RE, Heppel NH, Grimstead JW, Fegan C, Jackson GH, Hills R, Allan JM, Pratt G, Pepper C, Baird DM (2017) Telomere length is a critical determinant for survival in multiple myeloma. Bri J Haematol 178(1):94–98
Panero J, Dos Santos PC, Slavutsky IR (2017) Telomere protein complexes and their role in lymphoid malignancies. Front Biosci 9:17–30
de la Guardia RD, Catalina P, Panero J, Elosua C, Pulgarin A, López MB, Ayllón V, Ligero G, Slavutsky I, Leone PE (2012) Expression profile of telomere-associated genes in multiple myeloma. J Cellular Mol Med 16(12):3009–3021
Giaccherini M, Macauda A, Orciuolo E, Rymko M, Gruenpeter K, Dumontet C, Raźny M, Moreno V, Buda G, Beider K, Varkonyi J (2021) Genetically determined telomere length and multiple myeloma risk and outcome. Blood Cancer J 11(4):1
Chen YH, Magalhaes MC (1990) Hypoalbuminemia in patients with multiple myeloma. Arch Intern Med 150(3):605–610